Published in
Taylor and Francis Group, Expert Opinion on Biological Therapy, 1(21), p. 97-104, 2020
DOI: 10.1080/14712598.2020.1839045
Links
Tools
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
Journal article published in 2020 by
Daniela Pugliese 
,
Luisa Guidi,
Giuseppe Privitera,
Lorenzo Bertani,
Barbara Tolusso ,
Luigi Giovanni Papparella,
Simona Maltinti,
Clara Di Mario,
Sara Onali,
Linda Ceccarelli,
Gian Lodovico Rapaccini,
Franco Scaldaferri,
Elisa Gremese,
Antonio Gasbarrini ,
Francesco Costa
and other authors.
,
Luisa Guidi,
Giuseppe Privitera,
Lorenzo Bertani,
Barbara Tolusso ,
Luigi Giovanni Papparella,
Simona Maltinti,
Clara Di Mario,
Sara Onali,
Linda Ceccarelli,
Gian Lodovico Rapaccini,
Franco Scaldaferri,
Elisa Gremese,
Antonio Gasbarrini ,
Francesco Costa
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 